Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center — Los Angeles, California

Public research footprint of Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Recurrent Rhabdoid Tumor · Recurrent Malignant Germ Cell Tumor · Recurrent Malignant Glioma · Refractory Rhabdoid Tumor

Recently updated registry entries

NCT07232069 — PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis (Recruiting)
NCT04320888 — Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic… (Active Not Recruiting)
NCT03907488 — Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.